Drg Stimulator denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for drg stimulator are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied a Dorsal Root Ganglion Stimulator as Duplicate Therapy

A "duplicate therapy" denial for a dorsal root ganglion (DRG) stimulator means BCBS determined that the patient is already receiving a treatment it considers equivalent or overlapping — most commonly conventional spinal cord stimulation (SCS) or another implanted neuromodulation device. BCBS may also apply this rationale if the patient has had a recent trial of a similar device. This denial type is distinct from an "experimental" denial — it does not challenge the technology itself but argues the specific patient's situation does not warrant an additional or different device.

## Why This Is Appealable

DRG stimulation and traditional SCS are distinct technologies targeting different anatomical structures and different pain distributions. DRG stimulation is specifically indicated for conditions — such as complex regional pain syndrome (CRPS) and focal neuropathic pain syndromes — where conventional SCS has limited anatomical reach or has failed. A duplicate-therapy denial can be overturned by demonstrating that the prior or concurrent therapy is not clinically equivalent for this patient's specific condition and pain distribution.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial. BCBS must respond within 30 days for pre-service standard requests, 72 hours for urgent/expedited, and 60 days for post-service claims.
• External review (ACA §2719): Request independent external review within 4 months of the final internal denial. An IRO — not BCBS — makes the binding decision.
• ERISA §503 (self-funded plans): Full-and-fair review rights apply for employer-sponsored self-funded plans.
• State external review laws: Depending on the state, additional protections or timelines may apply — check your state insurance commissioner's website.

## Documentation to Gather

1. Diagnosis specificity documentation — records establishing the exact pain condition (e.g., CRPS Type I or II, focal peripheral neuropathy), its anatomical distribution, and why this distribution makes DRG stimulation the appropriate modality. 2. Prior therapy history and outcomes — documented records of prior or concurrent neuromodulation attempts, including dates, device type, stimulation parameters trialed, and objective outcome measures showing inadequate response. 3. Prescriber/implanting physician letter — a detailed letter explaining the clinical distinction between DRG stimulation and the therapy BCBS considers duplicative, specific to this patient's anatomy and condition. 4. Trial stimulation results — if a DRG trial was performed, include objective pain and functional outcome data from the trial period. 5. BCBS's duplicate-therapy policy — obtain the current version to ensure the appeal addresses each criterion directly.

## Criteria-Mapping Structure

| BCBS Criterion | Your Documentation | |---|---| | Prior/concurrent therapy identified by BCBS | [Treatment records with dates] | | Clinical distinction between modalities | [Physician letter, anatomical rationale] | | Inadequate response to prior therapy | [Outcome measures, chart notes] | | Diagnosis specificity supporting DRG over SCS | [Diagnostic records, specialist evaluation] |